PROŠIRENA BOLEST DIFERENTOVANOG TIREOIDNOG KARCINOMA ZBOG ODLAGANJA TOTALIZACIJE TIREOIDEKTOMIJE PRIKAZ SLUČAJA

Similar documents
THYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine

YCN Thyroid NSSG. *** VALID ON DATE OF PRINTING ONLY - all guidelines available at *** page 1 of 8 version number: 1.

4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.

Current Issues in Thyroid Cancer Surgery in 2017

How good are we at finding nodules? Thyroid Nodules Thyroid Cancer Epidemiology Initial management Long-term follow up Disease-free status

Pediatric Thyroid Cancer Lung Metastases. Liora Lazar MD

WTC 2013 Panel Discussion: Minimal disease

Gerard M. Doherty, MD

Thyroid Surgery: Lobectomy, total thyroidectomy, LN biopsies or only watchful waiting?

Thyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose.

Thyroid INTRODUCTION ANATOMY SUMMARY OF CHANGES

THYROID CANCER IN CHILDREN

Risk Adapted Follow-Up

Preoperative Evaluation

Differentiated Thyroid Carcinoma

Papillary Thyroid Microcarcinoma Presenting as Horner s Syndrome: A Novel Clinical Presentation

Persistent & Recurrent Differentiated Thyroid Cancer

Dynamic Risk Stratification:

Thyroid carcinoma. Assoc. prof. V. Marković, MD, PhD Assoc. prof. A. Punda, MD, PhD D. Brdar, MD, nucl. med. spec.

Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer

Management guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007

Mandana Moosavi 1 and Stuart Kreisman Background

Research Article Papillary Thyroid Cancer, Macrofollicular Variant: The Follow-Up and Analysis of Prognosis of 5 Patients

What you need to know about Thyroid Cancer

Thyroid and Adrenal Gland

Review Article Thyroidectomy and Lymph Node Dissection in Papillary Thyroid Carcinoma

PEDIATRIC Ariel Katz MD

Review Article Management of thyroid carcinoma Alauddin M, Joarder AH

Review Article Management of papillary and follicular (differentiated) thyroid carcinoma-an update

I-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER

Thyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary

Thyroid remnant volume and Radioiodine ablation in Differentiated thyroid carcinoma.

Case 4: Disseminated bone metastases from differentiated follicular thyroid cancer

Dr J K Jekel Dept. Surgery University of Pretoria

2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines

Differentiated Thyroid Cancer: Initial Management

The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology

- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer

Research Article A Study on Central Lymph Node Metastasis in 543 cn0 Papillary Thyroid Carcinoma Patients

131-I Therapy Planning in Thyroid Cancer: The role of diagnostic radioiodine scans

Multi-Organ Distant Metastases in Follicular Thyroid Cancer- Rare Case Report

Clinical Study Prognosis of Multifocal Papillary Thyroid Carcinoma

Distant and Lymph Node Metastases of Thyroid Nodules with No Pathological Evidence of Malignancy: A Limitation of Pathological Examination

Clinical Guidance in Thyroid Cancers. Stephen Robinson Imperial at St Mary s On behalf of BTA

34 year-old Female with Thyroid Cancer

Minimalistic Initial Therapy Options For Low Risk Papillary Thyroid Cancer

40 TH EUROPEAN CONGRESS 0F CYTOLOGY LIVERPOOL, UK October 2-5, 2016

Thyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas.

AGGRESSIVE VARIANTS OF PAPILLARY THYROID CARCINOMA DIAGNOSIS AND PROGNOSIS

10/24/2008. Surgery for Well-differentiated Thyroid Carcinoma- The Primary

Reference No: Author(s) Approval date: October committee. September Operational Date: Review:

Thyroid nodules. Most thyroid nodules are benign

Case Scenario 1: Thyroid

Long Term Follow-Up for Differentiated Thyroid Cancer: The Mayo Experience

Volume 2 Issue ISSN

An Unexpected Cause of Hypoglycemia

Surgical Treatment for Papillary Thyroid Carcinoma in Japan: Differences from Other Countries

3/29/2012. Thyroid cancer- what s new. Thyroid Cancer. Thyroid cancer is now the most rapidly increasing cancer in women

Reoperative central neck surgery

1. Protocol Summary Summary of Trial Design. IoN

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules

Case Report Unexpected Bone Metastases from Thyroid Cancer

Research Article Therapeutic Outcomes of Patients with Multifocal Papillary Thyroid Microcarcinomas and Larger Tumors

Disclosures Nodal Management in Differentiated Thyroid Carcinoma

American Head and Neck Society - Journal Club Volume 22, July 2018

Case 5: Thyroid cancer in 42 yr-old woman with Graves disease

Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer

Four Cases of Malignant Pleural Effusion in Patients with Papillary Thyroid Carcinoma

42 yr old male with h/o Graves disease and prior I 131 treatment presents with hyperthyroidism and undetectable TSH. 2 hr uptake 20%, 24 hr uptake 50%

Dilemmas in Cytopathology and Histopathology

The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology

A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study

Canadian Scientific Journal. Intraoperative color detection of lymph nodes metastases in thyroid cancer

Management of Recurrent Thyroid Cancer

Thyroid and Parathyroid Disease. RTC Conference Christina Edwards Bailey Faculty: Dr. Carmen Solorzano April 2, 2010

What s an NIFTP? Keeping Up To Date in Thyroid 2018

Imaging in Thyroid Cancer

Imaging in Pediatric Thyroid disorders: US and Radionuclide imaging. Deepa R Biyyam, MD Attending Pediatric Radiologist

Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan

Thyroid Pathology: It starts and ends with the gross. Causes of Thyrophobia. Agenda. Diagnostic ambiguity. Treatment/prognosis disconnect

International Czech and Slovak cooperation in the treatment of patients with differentiated thyroid cancer

Clinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease

Managing Thyroid Microcarcinomas

Approach to Thyroid Nodules

Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD

Thyroid Nodules. Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA

Evaluation and Management of Thyroid Nodules. Overview of Thyroid Nodules and Their Management. Thyroid Nodule detection: U/S versus Exam

QUANTITATIVE MORPHOLOGY AS A PROGNOSTIC FACTOR IN FELINE SPONTANEOUS CUTANEOUS SQUAMOUS CELL CARCINOMAS

Changing trends in the management of well-differentiated thyroid carcinoma in Korea

CAP Cancer Protocol and ecc Summary of Changes for August 2014 Thyroid Agile Release

Thyroid and Parathyroid Surgery

Disclosures. Learning objectives. Case 1A. Autoimmune Thyroid Disease: Medical and Surgical Issues. I have nothing to disclose.

5/3/2017. Ahn et al N Engl J Med 2014; 371

Case Report Tumor-to-Tumor Metastasis: Lung Carcinoma Metastasizing to Thyroid Neoplasms

Well-differentiated Thyroid Cancer. Anton Sharapov, R4

Thyroid Cancer: Imaging Techniques (Nuclear Medicine)

Index. radiologic.theclinics.com. Note: Page numbers of article titles are in boldface type.

Differentiated Thyroid Cancer: Reclassification of the Risk of Recurrence Based on the Response to Initial Treatment

저작권법에따른이용자의권리는위의내용에의하여영향을받지않습니다.

Key Topics in Thyroid Cancer Worldwide epidemic What Should the Endocrinologist and Surgeon do?

Transcription:

58 MEDICINSKI GLASNIK / str. 58-61 Nenad Laketić 1, Kata Kovačić, Aleksandar Simić PROŠIRENA BOLEST DIFERENTOVANOG TIREOIDNOG KARCINOMA ZBOG ODLAGANJA TOTALIZACIJE TIREOIDEKTOMIJE PRIKAZ SLUČAJA Apstrakt: Diferentovani tireoidni karcinomi predstavljaju najčešće karcinome u tireoidnoj patologiji. Najčešći DTC je papilarni karcinom koji pokazuje tendenciju širenja i davanja metastaza limfnim putem. Pored širenja osnovnog oboljenja iz primarnog fokusa u lokalne i regionalne limfne žlezde uočava se tendencija intraglandularne limfogene diseminacije bolesti, kao i multicentrični karakter karcinoma. Iz ovog razloga nakon postavljanja dijagnoze papilarnog karcinoma štitaste žlezde terapija izbora bi trebalo biti totalna tireoidektomija (sa eventualnom disekcijom vrata), uz dopunsko lečenje radioaktivnim jodom. Rad: Diferentovani tireoidni karcinomi su najčešći od svih karcinoma štitaste žlezde i čine oko 90 %, najlakše se dijagnostikuju i najbolje leče. Papilarni tireoidni karcinomi se javljaju u 75 % slučajeva, folikularni tireoidni karcinomi u 10 % i Hürthl cell karcinomi u oko 2 4 % slučaja. Pacijentkinja G. K. (1990) se javila prvi put kod lekara 2009. godine zbog uočene nodozne strume desnog lobusa. Urađena FNA ukazala je na benignu promenu štitaste žlezde. Pacijentkinja je adekvatno dijagnostički obrađena i septembra 2009. godine učinjena desna lobektomija. Definitivni PH nalaz je ukazao na papilarni karcinom (klasični tip) 40mm. Nakon operacije je uvedena supstituciona terapija. Kompletizacija tireoidektomije nije savetovana. Zbog limfadenopatije desne strane vrata pacijentkinja je operisana februara 2015, kada je učinjena leva hemitireoidektomija (kompletirana totalna tireoidektomija) i funkcionalna disekcija desne strane vrata. 1 Specijalna bolnica Čigota, Zlatibor, laketic.cigota@gmail.com

PROŠIRENA BOLEST DIFERENTOVANOG TIREOIDNOG KARCINOMA ZBOG ODLAGANJA... 59 Definitivni PH nalaz: Levi lobus štitaste žlezde u kome se nalazi nekoliko sitnih fokusa papilarnog karcinoma štitaste žlezde prečnika do 1mm, što predstavlja intraglandularnu limfogenu diseminaciju karcinoma. Jedan od fokusa se nalazi i u okolnom vezivno-vaskularnom periglandularnom tkivu. Limfni nodusi desne strane vrata: od ukupno izolovanih 12 LN u 5 LN se nalaze metastaze karcinoma. Limfni nodus iz račve karotide sadrži metastaze karcinoma. Juna 2015. godine u našoj ustanovi primila terapijsku dozu I-131 od 5,55 GBq. Na postterapijskom scintigramu uočeno više konfluentnih zona nakupljanja radioaktivnog joda od submentalnog regiona do jugularne jame. Pri aplikaciji Th-doze TSH=64.0 miu/l, Tg>300ng/ml, antitgat=20 U/ml. Slika 1. Ciljani postterapijski snimak glave i vrata (jun 2015) U okviru pripreme za drugu reoperaciju urađen MDCT (septembar 2015): Mediosagitalno ispod donjeg pola tireoidne hrskavice i uz prednju konturu traheje diferencira se kružna promena, hipodenozna, veličine 11 x 7mm. U loži desnog režnja štitaste žlezde i pozadi hiperdenozna formacija 22 x 14mm. Kaudalnije uz anteromedijalnu konturu traheje desno hiperdenozna nodusna zona 15 x 12mm. Druga reoperacija oktobra 2015. godine, kada je učinjena centralna disekcija sa desne strane, ekstirpacija LGL lateralno od desne VCI, ekstirpacija LGL prelaringealno.

60 MEDICINSKI GLASNIK / str. 58-61 Definitivni PH nalaz: LN desne strane vrata: Dva LN sa metastazom papilarnog karcinoma štitaste žlezde. Prelaringealni LN: Od 2 LN u 1 LN se nalaze metastaze papilarnog karcinoma. LN centralno: od 12 LN u 11 LN se nalaze metastaze papilarnog karcinoma. Druga doza I-131 od 5,55 GBq aplikovana je krajem januara 2016. Pri aplikaciji Th-doze TSH>75.0 miu/l, Tg=76.8 ng/ml, antitgat=20 U/ml. Na postterapijskom scintigramu uočavaju se dva fokusa nakupljanja radioaktivnog joda, jedan u jugularnoj jami, a druga iza manubrijuma grudne kosti. Slika 2. Ciljani postterapijski snimak glave i vrata (februar2016) Nakon prijema doze u terapiju ponovo uvedena supresivno-supstituciona terapija preparatima levotiroksina. Diskusija: Papilarni karcinom štitaste žlezde predstavlja najčešći karcinom štitaste žlezde sa odličnim prognostičkim pokazateljima. Naime, petogodišnje preživljavanje je između 97 % i 99 % pacijenata. Iz ovog razloga u literaturi se sve češće sreću dileme koliko je postoperativna terapija radioaktivnim jodom zaista neophodna. S druge strane, karakteristike papilarnog karcinoma koje govore u prilog radikalnog lečenja (totalna tireoidektomija i dopunska terapija radioaktivnim jodom) su čest multicentrični karakter neoplazme, tendencija intratireoidnog limfogenog širenja, kao i tendencija širenja u lokalne i regionalne limfne žlezde. Od manjeg značaja (ali ne i zanemarljivog) je i mogućnost dediferencijacije papilarnog karcinoma u naročito agresivan anaplastični karcinom.

PROŠIRENA BOLEST DIFERENTOVANOG TIREOIDNOG KARCINOMA ZBOG ODLAGANJA... 61 Rizične grupe prema protokolu za lečenje radioaktivnim jodom su osobe mlađe od 15 i starije od 45 godina. Iskustva naše ustanove govore da je populacija koja je pod najvećim rizikom da ima proširenu ili upornu bolest upravo ona između 15 i 30 godina starosti. U ovom radu prikazali smo slučaj mlade ženske osobe kojoj je urađena hemitireoidektomija i postavljena je dijagnoza papilarnog karcinoma. Šest godina nakon prve operacije urađena je nova operacija kada je odstranjen preostali režanj i patološke limfne žlezde kontralateralne strane vrata. Fokusi papilarnog karcinoma u režnju su promera do 1mm, dok su patološke limfne žlezde bile promera oko 20mm. Ne može se očekivati da su fokusi karcinoma od 1mm dali metastaze kontralateralno, koje su navedenih dimenzija. Pretpostavka je da patološke lgl, koje su na istoj strani kao primarni karcinom (operisan 2009), predstavljaju kasnu manifestaciju proširene bolesti iz ovog primarnog fokusa. Fokusi mikrokarcinoma u suprotnom režnju predstavljaju intraglandularno limfogeno širenje karcinoma, kako se patolog izjasnio. Kako se patohistološki ne može razlikovati intratireoidno proširena bolest od de novo multifokalne neoplazme bez posebnih bojenja, u obzir dolazi i multifokalnost karcinoma u levom lobusu. Zaključak je da je 2009. godine kompletirana tireoidektomija i da je primenjena terapija radioaktivnim jodom desilo bi se nekoliko pozitivnih situacija: 1. sprečilo bi se intratireoidno limfogeno širenje karcinoma / pojava novih fokusa u okviru multicentričnog karcinoma; 2. izvršila bi se ablacija tkivnih ostataka tireoidne lože i sprečila pojava novih fokusa karcinoma dalje tokom života; 3. izvršilo bi se terapijsko delovanje na (pretpostavka) mikrometastaze u limfnim čvorovima iste strane. Zaključak: Nakon postavljanja dijagnoze papilarnog karcinoma štitaste žlezde terapija izbora bi trebalo biti totalna tireoidektomija (sa eventualnom disekcijom vrata), uz dopunsko lečenje radioaktivnim jodom. Jedino na ovaj način možemo smanjiti verovatnoću da se bolest proširi i/ili postane inoperabilna. Takođe, praćenje pacijenata u smislu nivoa markera u krvi (Tg i antitgat) je značajno lakše. Literatura: 1. Robert E. Henkin, Nuclear Medicine, Mosby, 2006. 2. Emilio Bombardieri et al, Advances in Nuclear Oncology, Informa Healthcare 2007. 3. The Patophysiologic Baics of Nuclear medicine (Second Edition), Abdelhamid Elgazzar, Springer, 2006. 4. Georg F. W. Scheumann et al., Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer, World Journal of Surgery, 1993.

62 MEDICINSKI GLASNIK / str. 62-65 Nenad Laketic 1, Kata Kovacic, Aleksandar Simic DISSEMINATION OF DIFFERENTIATED THYROID CARCINOMA DUE TO PROLONGED TOTALIZATION OF THYROIDECTOMY CASE REPORT Abstract: Differentiated thyroid carcinomas (DTC) are the most common carcinomas in thyroid patology. The most common DTC is papillary thyroid carcinoma (PTC) which tends to spread lymphogenously. Beside spreading of malignant disease from the primary focus toward local and regional lymph nodes, intrathyroid lymphogenous spreading is also seen, as well as multifocal character of PTC. From this reason, after the diagnosis of PTC is established, desired therapy should be total thyroidectomy (with/without neck dissection) along with additional radioiodine therapy. Work: Differentiated thyroid carcinomas (DTC) are the most common carcinomas in thyroid patology. They represent 90% of all thyroid carcinomas. They are relatively easy to diagnose and have good prognosis. PTC occurs in 75%, follicular in 10% and Hurthle cell carcinomas in 2-4%. Female patient G.K. (1990) was diagnosed with nodular goiter of the right thyroid lobe in 2009. Although FNAC was benign, right lobectomy was performed the same year. Histopathological exam showed classic type of PTC 40mm in diameter. After the surgery patient was prescribed L-thyroxin supstitution. Totalization of thyroidectomy has not been advised. In 2015 patient underwent surgery for the second time due to a number of pathological lymph nodes of the right side of neck. Left lobectomy was performed along with extraction of lymph nodes of the right side of the neck. Definitive histopathological findings: Left lobe of the thyroid gland with several focuses of papillary thyroid carcinoma (up to 1mm in diameter) which represent intrathyroid lymphogenic dissemination of the disease. One focus is in adjacent connective and vascular tissue located outside of the thyroid gland. 1 Special hospital for thyroid diseases and metabolic diseases, Zlatibor, laketic.cigota@gmail.com

DISSEMINATION OF DIFFERENTIATED THYROID CARCINOMA DUE TO PROLONGED TOTALIZATION... 63 Lymph nodes (right side of the neck) among 12 LN, 5 had PTC metastasis. Lymph node from the carotid bifurcation PTC metastasis. In June 2015 patient received therapeutic dose of I-131 (5,55 GBq) in our institution. WBS after the therapy showed multiple focuses of radioiodine accumulation along the mid-line of the neck: from submental region down to jugular notch. Blood parameters were: TSH=64.0 miu/l (0.3-4.2), Tg>300ng/ml, antitgat=20 U/ml. Picture 1. Posttherapeutic targeted scan of the head and neck (June 2015) Second reoperation was performed in October 2015. with the neck dissection (right central, right lateral and laryngeal anterior). Definitive histopathological findings: 1. Right lateral LN: 2 LN with PTC metastasis. 2. Right central LN: 11 LN out of 12 LN had PTC metastasis 3. Laryngeal anterior LN: one out of 2 LN had PTC metastasis. The second dose of I-131 (5,55 GBq) was received at the end of January 2016. Blood parameters were: TSH>75.0 miu/l, Tg=76.8 ng/ml, antitgat=20 U/ml. WBS after the therapy showed two focuses of I-131 accumulation: one in jugular notch and the other one behind manubrium.

64 MEDICINSKI GLASNIK / str. 62-65 Picture 2. Posttherapeutic targeted scan of the head and neck (February 2016) Discussion: Papillary thyroid carcinomas (PTC) are the most common carcinomas in thyroid patology. They are relatively easy to diagnose and have good prognosis. Five-year survival is between 97% and 99% of patients. Because of that, we can find more and more papers where is discussed whether there is a need for radicality (total thyroidectomy and radioiodine therapy) in this carcinoma at all. On the other hand, PTC characteristics that are speaking in favor of radicality are: multifocal PTC which is not rare, intrathyroid lymphogenic dissemination and tendency of dissemination in local and regional lymph nodes. Minor importance has tendency of poorly differentiated papillary carcinoma to dedifferentiate into very agressive anplastic carcinoma. High-risk population according to DTC treatment protocols are patients younger than 15 and older than 45 years. Our institution experience shows that the population which has the highest rate of disseminated disease or prolonged disease is between 15 and 30 years of life. This work presented the case of a young female patient who underwent right hemithyroidectomy and was diagnosed with papillary thyroid carcinoma. Six years after the first surgery she had another one when the surgeon has completed thyroidectomy (left lobe) and has extracted pathological lymph nodes on the right side of the neck. PTC focuses in the left lobe were up to 1mm in diameter while the lymph nodes were around 2cm in diameter. It can not be expected that these focuses in the left lobe have given metastasis in contralateral side of the neck which are this big.

DISSEMINATION OF DIFFERENTIATED THYROID CARCINOMA DUE TO PROLONGED TOTALIZATION... 65 We assume that lymph nodes, which were on the same side of the neck as the first PTC from 2009, represent late manifestation of disseminated disease from the primary focus. Focuses of microcarcinoma in left lobe present intrathyroid lymphogenous dissemination, as histopathologic findings showed. But, we can not distinguish between lymphogenous dissemination and new multicentric focuses without certain histopathologic procedures (which are not commonly done). Because of this, microcarcinoma in the left lobe could be de nuovo formed muticentric neoplasm. Our conclusion is: if totalization of the thyroidectomy and additional radioiodine therapy has been done right after the first surgery in 2009., there would be several positive outcomes: intrathyroid dissemination of the disease/appearance of new focuses could be prevented with radioiodine ablation in thyroid bed appearance of new focuses during the life could be prevented radioiodine therapy could have had therapeutic effect on (as we suppose) micrometastasis in the lymph nodes on the same side of the neck Conclusion: After the PTC diagnoses has been established the desired therapy should be total thyroidectomy along with additional radioiodine therapy. Only this way we can prevent the disease to disseminate or to become inoperable. Follow up of the patient in terms of tumor markers (thyroglobuline, antitg antibodies) is facilitated, also. References 1. Nuclear Medicine, Robert E. Henkin, Mosby, 2006 2. Advances in Nuclear Oncology, Emilio Bombardieri et al, Informa Healthcare 2007. 3. The Patophysiologic Baics of Nuclear medicine (Second Edition), Abdelhamid Elgazzar,Springer,2006 4. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer, Georg F. W. Scheumann et al., World Journal of Surgery, 1993.